Compare Suncor Energy Inc. (SU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs BIO-TECHNE Corp — how do they compare? Suncor Energy Inc. trades at $62.32 (market cap $72.86B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Suncor Energy Inc. is far larger — about 6.5× BIO-TECHNE Corp's market cap, and Suncor Energy Inc. pays the higher dividend (2.71%). Which is the better fit depends on your goals.
| SU | TECH | |
|---|---|---|
Market Cap | $72.86B | $11.16B |
Sector | Energy | Health |
52-Week High | $69.73 | $72.12 |
52-Week Low | $38.17 | $43.31 |
Enterprise Value | $80.99B | $11.24B |
Dividend Yield | 2.71% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
